Warrants not THAT great
Research Triangle Park, NC, August 25, 2011 – Adherex Technologies Inc. (TSX:AHX, Pink Sheets: ADHXF), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today announced the completion of the consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidation common share for every eighteen (18) pre-consolidation common shares. The consolidation will reduce the number of shares of the company’s outstanding common shares from approximately 452.8 million, as of the filing date of the company’s most recent Quarterly Report on Form 10-Q, to approximately 25.2 million. Further, as a result of the consolidation, Adherex’s outstanding common share purchase warrants will be exercisable on the basis that each eighteen (18) warrants will entitle the holder to purchase one (1) common share of the Company at an exercise price of $1.44 per share.